Half-year report · HY
2158.TEDINET S100X4KF
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥6m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥290m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥23m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥544m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥20m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥296m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥555m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥73m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥206m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥102m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥753m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥369m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥254m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥123m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥689m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥913m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥564m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.86 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.25 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥5.24 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 39.1% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| DXreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| DXreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥61m |
| Life Science AIreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥274m |
| Life Science AIreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥216m |
| Risk Managementreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.9bn |
| Risk Managementreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥150m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | −¥6m |
| DXreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥154m |
| DXreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥34m |
| Life Science AIreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥140m |
| Life Science AIreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥122m |
| Risk Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| Risk Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥290m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 564
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 2850784000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 154193000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3144721000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 3144721000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | 139744000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 2850784000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 154193000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3144721000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 3144721000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | -122202000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 378785000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 33549000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 290132000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 290132000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | 273962000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 1935443000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 1165932000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3375338000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 3375338000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | － | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | 273962000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 1935443000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 1165932000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 3375338000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration | 3375338000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05700-000LifeScienceAIReportableSegmentMember | -216109000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05700-000RiskManagementReportableSegmentMember | 149622000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05700-000DXReportableSegmentMember | 60695000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | -5791000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | InterimDuration | -5791000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |